ReviewPediatric rheumatology online journal2016
Juvenile idiopathic arthritis-associated uveitis.
Review in Pediatric rheumatology online journal, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Tumor necrosis factor (TNF) inhibitors for juvenile idiopathic arthritis-associated uveitis.The Cochrane database of systematic reviews · 2022Pooled it
- Defining outcome measures in juvenile idiopathic arthritis associated uveitis by a systematic review analysis: do we need a consensus?Pediatric rheumatology online journal · 2019Pooled it
- Effectiveness and Safety of Baricitinib for Juvenile Idiopathic Arthritis-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive Uveitis.Arthritis care & research · 2026Trial
- Identifying outcome measures for clinical trials in juvenile idiopathic arthritis associated uveitis for the MIWGUC proposal: a scoping review to create domains from existing outcome measures.Pediatric rheumatology online journal · 2026Article
- Systemic Immunomodulatory Therapy, Anterior Chamber Inflammation, and the Use of Topical Corticosteroids in Juvenile Idiopathic Arthritis-Associated Uveitis: A Long-Term Real-Life Observational Study.Journal of clinical medicine · 2026Article
- Machine learning for screening and predicting the risk of developing uveitis in juvenile idiopathic arthritis.Pediatric rheumatology online journal · 2025Article
- Juvenile idiopathic arthritis during 20 years in Sweden: Characteristics of children, therapy interventions, occurrence of uveitis and ocular complications.Acta ophthalmologica · 2025Article
- Assessment of choroidal vascularity index in juvenile idiopathic arthritis: implications for disease monitoring.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2025Article
- Treatment outcomes of a Swiss non-infectious paediatric uveitis cohort: retrospective study over ten years.Journal of ophthalmic inflammation and infection · 2025Article
- Epidemiology and comorbidity of juvenile idiopathic arthritis in Poland- a nationwide study.Pediatric rheumatology online journal · 2025Article
- Clinical Characteristics and Prognosis of Juvenile Idiopathic Arthritis-Associated Uveitis: A Single-Center Retrospective Study.Clinical ophthalmology (Auckland, N.Z.) · 2025Article
- Ocular involvement and visual prognosis in juvenile idiopathic arthritis associated uveitis.International journal of ophthalmology · 2025Article
- Development of a machine learning-based predictive nomogram for screening children with juvenile idiopathic arthritis: a pseudo-longitudinal study of 223,195 children in the United States.Frontiers in public health · 2025Article
- Integration of Genetic and Clinical Risk Factors for Risk Classification of Uveitis in Patients With Juvenile Idiopathic Arthritis.Arthritis & rheumatology (Hoboken, N.J.) · 2024Article
- Extraarticular manifestations of juvenile idiopathic arthritis and their impact on health-related quality of life.Clinical rheumatology · 2024Article
- A clearer vision: insights into juvenile idiopathic arthritis-associated uveitis.Proceedings (Baylor University. Medical Center) · 2024Article
- Defining a therapeutic range for adalimumab serum concentrations in the management of pediatric noninfectious uveitis, a step towards personalized treatment.Pediatric rheumatology online journal · 2023Observational
- Evaluation of Uveitis Induced in Rats by a Type I Collagen Peptide as a Model for Childhood Arthritis-associated Uveitis.Comparative medicine · 2023Article
- Encouraging visual outcomes in children with idiopathic and JIA associated uveitis: a population-based study.Pediatric rheumatology online journal · 2023Article
- Natural autoimmunity in oligoarticular juvenile idiopathic arthritis.Pediatric rheumatology online journal · 2023Article
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease of childhood, with JIA-associated uveitis its most common extra-articular manifestation. JIA-associated uveitis is a potentially sight-threatening condition and thus carries a considerable risk of morbidity. The aetiology of the condition is autoimmune in nature with the predominant involvement of CD4(+) T cells. However, the underlying pathogenic mechanisms remain unclear, particularly regarding interplay between genetic and environmental factors. JIA-associated uveitis comes in several forms, but the most common presentation is of the chronic anterior uveitis type. This condition is usually asymptomatic and thus screening for JIA-associated uveitis in at-risk patients is paramount. Early detection and treatment aims to stop inflammation and prevent the development of complications leading to visual loss, which can occur due to both active disease and burden of disease treatment. Visually disabling complications of JIA-associated uveitis include cataracts, glaucoma, band keratopathy and macular oedema. There is a growing body of evidence for the early introduction of systemic immunosuppressive therapies in order to reduce topical and systemic glucocorticoid use. This includes more traditional treatments, such as methotrexate, as well as newer biological therapies. This review highlights the epidemiology of JIA-associated uveitis, the underlying pathogenesis and how affected patients may present. The current guidelines and criteria for screening, diagnosis and monitoring are discussed along with approaches to management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.